Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 29;17(1):180.
doi: 10.1186/s12874-017-0460-z.

Abstract analysis method facilitates filtering low-methodological quality and high-bias risk systematic reviews on psoriasis interventions

Francisco Gómez-García  1   2 , Juan Ruano  3   4 , Macarena Aguilar-Luque  1 , Patricia Alcalde-Mellado  5 , Jesús Gay-Mimbrera  2 , José Luis Hernández-Romero  1   2 , Juan Luis Sanz-Cabanillas  1   2 , Beatriz Maestre-López  5 , Marcelino González-Padilla  1   2 , Pedro J Carmona-Fernández  2 , Antonio Vélez García-Nieto  1   2 , Beatriz Isla-Tejera  2   6
Affiliations

Abstract analysis method facilitates filtering low-methodological quality and high-bias risk systematic reviews on psoriasis interventions

Francisco Gómez-García et al. BMC Med Res Methodol. .

Abstract

Background: Article summaries' information and structure may influence researchers/clinicians' decisions to conduct deeper full-text analyses. Specifically, abstracts of systematic reviews (SRs) and meta-analyses (MA) should provide structured summaries for quick assessment. This study explored a method for determining the methodological quality and bias risk of full-text reviews using abstract information alone.

Methods: Systematic literature searches for SRs and/or MA about psoriasis were undertaken on MEDLINE, EMBASE, and Cochrane database. For each review, quality, abstract-reporting completeness, full-text methodological quality, and bias risk were evaluated using Preferred Reporting Items for Systematic Reviews and Meta-analyses for abstracts (PRISMA-A), Assessing the Methodological Quality of Systematic Reviews (AMSTAR), and ROBIS tools, respectively. Article-, author-, and journal-derived metadata were systematically extracted from eligible studies using a piloted template, and explanatory variables concerning abstract-reporting quality were assessed using univariate and multivariate-regression models. Two classification models concerning SRs' methodological quality and bias risk were developed based on per-item and total PRISMA-A scores and decision-tree algorithms. This work was supported, in part, by project ICI1400136 (JR). No funding was received from any pharmaceutical company.

Results: This study analysed 139 SRs on psoriasis interventions. On average, they featured 56.7% of PRISMA-A items. The mean total PRISMA-A score was significantly higher for high-methodological-quality SRs than for moderate- and low-methodological-quality reviews. SRs with low-bias risk showed higher total PRISMA-A values than reviews with high-bias risk. In the final model, only 'authors per review > 6' (OR: 1.098; 95%CI: 1.012-1.194), 'academic source of funding' (OR: 3.630; 95%CI: 1.788-7.542), and 'PRISMA-endorsed journal' (OR: 4.370; 95%CI: 1.785-10.98) predicted PRISMA-A variability. Reviews with a total PRISMA-A score < 6, lacking identification as SR or MA in the title, and lacking explanation concerning bias risk assessment methods were classified as low-methodological quality. Abstracts with a total PRISMA-A score ≥ 9, including main outcomes results and explanation bias risk assessment method were classified as having low-bias risk.

Conclusions: The methodological quality and bias risk of SRs may be determined by abstract's quality and completeness analyses. Our proposal aimed to facilitate synthesis of evidence evaluation by clinical professionals lacking methodological skills. External validation is necessary.

Keywords: AMSTAR; Abstract readability; Decision trees; Methodological quality; PRISMA for abstracts; Psoriasis; Quality of reporting; Systematic review.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Since our study did not collect primary data, no formal ethical assessment or informed consent were required.

Consent for publication

Not applicable.

Competing interests

FG-G has received honoraria for research from Pfizer, and for lecturing from AbbVie, Janssen-Cilag and Novartis; JR has received honoraria for lecturing and grants for research from Pfizer, honoraria for lecturing from Janssen-Cilag and Novartis, and other financial benefits from AbbVie and Novartis; AVG-N has received honoraria for lecturing from Pfizer, Novartis, AbbVie, and Janssen-Cilag, and other financial benefits from AbbVie, No- vartis, and Janssen-Cilag; JG-M, MA-L, JLS-C, PA-M, BM-L, PJC-F, MG-P, and BI-T have no disclosures. MA-L, JR, FG-G, and BI-T are members of the Cochrane Bias Methods Group and Skin Group.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram of article selection process
Fig. 2
Fig. 2
Plot of Likert scales with PRISMA-A. This graph shows the frequency distributions of responses to SR reporting assessment using PRISMA for Abstracts. This graph shows frequency distributions of responses (yes, no) to the 12 items of PRISMA for Abstracts
Fig. 3
Fig. 3
Frequency distributions of responses to reporting assessment using PRISMA for Abstracts comparing SR based on methodological quality and risk of bias. This panel of plots contains different graphs showing PRISMA for Abstracts results when reviews are subgrouped by ROBIS (a,b) and AMSTAR (d,d,e) classifications. (a-b) These plots display frequency distributions of responses (‘no’, ‘yes’) to PRISMA for Abstracts comparing reviews by risk of bias using ROBIS tool (‘high’ or ‘low’). (c-d) These plots show frequency distributions of PRISMA for Abstracts responses (‘no’ or ‘yes’) comparing reviews by AMSTAR-derived methodological quality levels (‘high’, ‘moderate’, or ‘low’)
Fig. 4
Fig. 4
Tree classification model of the methodological quality of SRs based on PRISMA-A total and per item scores. Each node shows from top to bottom the predicted class (high-moderate, low), the predicted probability of each class, and the percentage of observations in the node
Fig. 5
Fig. 5
Tree classification model of the bias risk of SRs based on PRISMA-A total and per item scores. Each node shows from top to bottom the predicted class (high, low), the predicted probability of each class, and the percentage of observations in the node
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Dias S, Welton NJ, Sutton AJ, Ades AE. Evidence synthesis for decision making 1: introduction. Med Decis Making. 2013;33:597–606. doi: 10.1177/0272989X13487604. - DOI - PMC - PubMed
    1. Abuabara K, Freeman EE, Dellavalle R. The role of systematic reviews and meta-analysis in dermatology. J Invest Dermatol. 2012;132:e2. doi: 10.1038/jid.2012.392. - DOI - PubMed
    1. Ioannidis JP. The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses. Milbank Q. 2016;94:485–514. doi: 10.1111/1468-0009.12210. - DOI - PMC - PubMed
    1. Goff KL, Karimkhani C, Boyers LN, Weinstock MA, Lott JP, Hay RJ, Coffeng LE, Norton SA, Naldi L, Dunnick C, Armstrong AW, Dellavalle RP. The Global Burden of Psoriatic Skin Disease. Br J Dermatol. 2015;172:1665–8. doi: 10.1111/bjd.13715. - DOI - PubMed
    1. Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J. Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. Br J Dermatol. 2017;176:594–603. doi: 10.1111/bjd.14814. - DOI - PubMed

Publication types